Nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2018.00253
Full Text
Open PDFAbstract
Available in full text
Date
July 24, 2018
Authors
Publisher
Frontiers Media SA